These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11600229)

  • 1. Prodrug strategies in cancer therapy.
    Denny WA
    Eur J Med Chem; 2001; 36(7-8):577-95. PubMed ID: 11600229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-activated prodrugs--a new approach to cancer therapy.
    Denny WA
    Cancer Invest; 2004; 22(4):604-19. PubMed ID: 15565818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
    Denny WA; Wilson WR
    J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral vectors for gene-directed enzyme prodrug therapy.
    Schepelmann S; Springer CJ
    Curr Gene Ther; 2006 Dec; 6(6):647-70. PubMed ID: 17168697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-glucuronidase-mediated drug release.
    de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
    Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Chen L; Waxman DJ
    Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hypoxia-activated prodrugs in cancer therapy.
    Denny WA
    Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
    Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
    Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.
    Nishi Y
    Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
    Lehouritis P; Stanton M; McCarthy FO; Jeavons M; Tangney M
    J Control Release; 2016 Jan; 222():9-17. PubMed ID: 26655063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.
    HariKrishna D; Rao AR; Krishna DR
    Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of anticancer prodrugs for reductive activation.
    Chen Y; Hu L
    Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.